CureMetrix

Bottom line

CureMetrix offers FDA-cleared artificial intelligence for mammography screening in two modes: cmTriage prioritizes worklists by cancer likelihood, and cmAssist functions as a computer-aided detection second reader. The platform stands out for detecting invasive lobular carcinoma, a breast cancer subtype notoriously difficult to see on mammography, and for quantifying breast arterial calcification as a cardiovascular risk marker. This dual capability extends the clinical value of routine mammography beyond cancer detection.

The system is validated across multiple vendors and institutions, but the evidence base remains narrow. Only three peer-reviewed studies appear in PubMed as of May 2026, none of them randomized controlled trials measuring recall rates or mortality outcomes. Clinician chatter is absent: zero mentions on Reddit's radiology or medicine communities suggest limited grassroots adoption or radiologist-facing deployment that hasn't reached primary care or social discussion.

Pricing is opaque. CureMetrix sells exclusively through enterprise contracts with no published per-exam or per-radiologist rates. Health system radiology departments with existing AI budgets and PACS integration capacity will find this approachable. Solo breast imaging practices and small hospital networks seeking transparent pricing should look elsewhere or be prepared to negotiate blind.

Why we picked it

FDA clearance for a mammography triage algorithm is not trivial. The 2022 multicenter validation study in the Journal of Breast Imaging confirmed performance across breast densities and lesion types, using retrospective screening mammograms from multiple institutions and mammography vendors. This suggests the algorithm generalizes beyond a single training site, a critical requirement for any diagnostic AI entering diverse clinical workflows.

The invasive lobular carcinoma detection capability addresses a genuine clinical gap. ILC accounts for roughly 10 percent of breast cancers but often presents as subtle architectural distortion rather than a discrete mass, making it harder for radiologists and traditional CAD systems to flag. The 2023 Cureus study evaluated CureMetrix specifically on biopsy-proven ILC cases and found the AI flagged lesions that human readers and older CAD systems missed.

Breast arterial calcification quantification is the platform's differentiator. The 2026 JACC Cardiovascular Imaging study introduced an age-adjusted percentile nomogram for BAC detected on routine mammography, positioning it as an incidental cardiovascular risk marker. Most mammography AI tools ignore arterial calcification or treat it as noise. CureMetrix quantifies it and ties it to cardiovascular event prediction, creating a second clinical output from a single screening exam.

The triage mode (cmTriage) offers workflow efficiency that radiologists understand. By scoring exams and surfacing high-suspicion cases first, it allows radiologists to concentrate attention where cancer likelihood is highest and defer lower-risk reads to the end of a worklist. For high-volume breast imaging centers facing radiologist shortages, this is a tangible operational gain, not just a detection quality improvement.

What it does well

The cmTriage workflow prioritization is practical for overloaded reading rooms. Radiologists receive a ranked worklist with high-suspicion exams flagged for immediate review. This reduces cognitive load during long reading sessions and ensures that the most concerning cases get fresh eyes first, before reader fatigue sets in. The 2022 validation study noted consistent performance across dense and non-dense breast tissue, suggesting the triage scoring does not degrade in challenging cases.

The cmAssist detection mode functions as a traditional CAD overlay, marking regions of interest on the mammogram. Unlike older CAD systems that generated excessive false positives, the AI-based approach in cmAssist appears more selective. The Cureus ILC study highlighted its ability to flag subtle architectural distortions that radiologists initially missed, leading to earlier detection in a cancer subtype where delays are common.

Breast arterial calcification quantification is clinically novel. The 2026 nomogram study demonstrated that BAC severity, when adjusted for age, correlates with cardiovascular events independently of traditional risk factors. This turns a screening mammogram into a dual-purpose exam: cancer detection plus cardiovascular risk stratification. For primary care physicians managing women's health, an incidental BAC score on a mammography report could trigger earlier cardiology referral or statin discussion, especially in patients without prior cardiac workup.

Multivendor and multicenter validation reduces deployment risk. The 2022 study tested CureMetrix across different mammography equipment manufacturers and hospital settings, demonstrating that the algorithm does not require site-specific retraining. This matters for health systems with mixed equipment fleets or multi-site networks where vendor lock-in to a single mammography brand is impractical.

Where it falls short

The evidence base is thin. Three peer-reviewed studies in four years is modest for an FDA-cleared diagnostic AI. None are randomized controlled trials measuring the impact on recall rates, false positives, or mortality outcomes in a prospective screening population. The validation studies are retrospective and performance-focused, not outcomes-focused. Buyers seeking Level 1 evidence to justify ROI will find gaps.

Clinician adoption signals are absent. Zero mentions on Reddit's radiology, medicine, or residency communities is unusual for a tool in clinical use since at least 2022. Either deployment is limited to a small number of enterprise customers, or the tool is radiologist-facing enough that it hasn't reached primary care physicians or generated organic discussion. Lack of grassroots chatter makes it harder to assess real-world satisfaction or pain points.

Pricing opacity creates friction. Enterprise-only contracts with no published tiers mean prospective buyers must engage sales before understanding cost structure. This is common in radiology AI, but it disadvantages small practices and academic centers with constrained procurement budgets. Hidden costs such as per-exam API calls, annual escalators, or PACS integration fees are not documented publicly, forcing buyers to negotiate without market benchmarks.

The platform appears narrowly scoped to breast imaging. There is no public evidence of CureMetrix expanding into chest CT, lung nodule detection, or other radiology domains where AI is proliferating. For health systems seeking a multi-modality AI partner, this single-specialty focus may require managing multiple vendor relationships instead of consolidating under one contract.

Deployment realities

PACS integration is mandatory. CureMetrix ingests DICOM images from the picture archiving and communication system and returns annotations or triage scores. IT teams must configure HL7 or FHIR interfaces, manage firewall rules for cloud-based AI processing, and ensure that AI-generated findings populate the radiologist's reading environment without manual export-import steps. Multivendor validation suggests the AI adapts to different PACS architectures, but integration still requires dedicated IT project management.

Radiologist training is non-trivial. Interpreting AI-generated regions of interest requires understanding the model's sensitivity and specificity profile. Radiologists must learn when to trust a flag, when to override it, and how to document AI-assisted reads for medicolegal purposes. The 2023 ILC study noted that AI flagged lesions radiologists initially dismissed, implying a learning curve where readers calibrate their confidence against the algorithm's output. Expect two to four weeks of supervised reading before solo deployment.

Workflow redesign for triage mode demands buy-in. Shifting from chronological worklists to AI-prioritized queues changes radiologist habits and may surface resistance from readers who prefer autonomy over algorithmic direction. Breast imaging centers must establish protocols for when triage scoring is binding versus advisory, how to handle AI system downtime, and whether to maintain parallel non-AI workflows for comparison during the validation phase. Change management is as important as technical implementation.

Pricing realities

CureMetrix does not publish per-exam, per-radiologist, or per-year pricing. The vendor listing notes enterprise-only contracts, implying volume-based negotiation. Comparable mammography AI platforms range from $20,000 to $150,000 annually for mid-sized imaging centers, with per-exam fees of $3 to $10 when billed separately. Without public benchmarks, buyers enter negotiations blind and must rely on competitive bids from iCAD, Lunit, or Therapixel to establish fair market value.

Hidden costs include PACS integration labor, radiologist training time, and ongoing support. IT teams may need 40 to 80 hours for initial deployment and firewall configuration. Radiologist training, if conducted by the vendor, can incur per-session fees or require travel to a CureMetrix site. Annual contracts likely include escalators tied to case volume or inflation indices, and exiting mid-contract may carry penalties or data portability restrictions not disclosed upfront.

ROI calculation depends on workflow efficiency gains. If cmTriage reduces average reading time by 10 percent per exam and a breast imaging center processes 10,000 mammograms annually, the time savings could free one radiologist for additional cases or allow earlier case completion. At a radiologist cost of $300,000 per year, a 10 percent efficiency gain is worth $30,000 annually. However, these savings accrue only if the center has unmet demand or can redeploy radiologist time productively. In a volume-capped environment, faster reads do not translate to revenue, making ROI harder to justify.

Compliance + integration depth

FDA clearance is confirmed in the 2022 Journal of Breast Imaging study, which explicitly refers to the algorithm as FDA-approved for mammography triage. This implies 510(k) clearance as a Class II medical device, the standard pathway for diagnostic AI. HIPAA compliance is expected but not publicly documented on the CureMetrix website. SOC 2 Type II and HITRUST certifications are common in radiology AI vendors but not listed in available materials, so buyers should request attestation reports during procurement.

PACS integration depth is multivendor but not EHR-native. The validation study tested CureMetrix across mammography equipment from multiple manufacturers, suggesting DICOM compatibility is robust. However, there is no evidence of direct Epic, Cerner, or Meditech integration for populating BAC cardiovascular risk scores into the patient's primary care flowsheet. Radiologists see the AI output in their reading environment, but primary care physicians relying on EHR-based mammography reports may not see structured BAC data unless the radiology report template is manually updated.

Specialty-society endorsements are absent. The American College of Radiology (ACR) and Society of Breast Imaging (SBI) have not issued public statements on CureMetrix specifically, though both organizations recognize AI in mammography as an emerging standard. Lack of society-level endorsement does not imply disapproval, but it means buyers cannot cite external validation from a trusted professional body when justifying adoption to hospital committees.

Vendor stability + roadmap

CureMetrix is US-based and has maintained FDA clearance since at least 2022, indicating regulatory competence and ongoing compliance with quality system regulations. The vendor's website lists mammography AI as the core product, with cmTriage and cmAssist as the two commercial offerings. Public funding rounds, acquisition history, and executive leadership are not documented in available sources, making it harder to assess financial stability or strategic direction.

The 2026 breast arterial calcification nomogram study suggests a roadmap toward cardiovascular risk integration. By positioning BAC as an incidental finding with clinical value, CureMetrix is expanding the use case beyond cancer detection. Future product directions could include tighter integration with cardiology risk calculators, automated primary care physician notifications for high BAC scores, or bundled cardiovascular screening packages. However, this is speculative; no public roadmap confirms these features.

Customer references are not published. The vendor website does not list testimonials, case studies, or named health system deployments. The multicenter validation study involved multiple institutions but did not name them, likely due to academic publication norms. Prospective buyers should request site visit opportunities and direct contact with existing customers during the evaluation phase, as third-party validation is otherwise unavailable.

How it compares

iCAD's ProFound AI is the most widely validated competitor, with more than 20 peer-reviewed studies including prospective trials measuring recall rate reduction and cancer detection rate improvement. ProFound AI integrates with multiple PACS vendors and has published customer testimonials from US health systems. It does not offer breast arterial calcification quantification, making CureMetrix the unique choice for cardiovascular risk stratification. However, iCAD's deeper evidence base and transparent pricing (published per-exam fees available through resellers) make it easier to justify to hospital committees.

Lunit INSIGHT MMG is a South Korean AI with strong international deployment, particularly in Europe and Asia. It offers detection and triage modes similar to CureMetrix and has published prospective studies in high-impact radiology journals. Lunit's pricing is also enterprise-focused, but the vendor provides public case studies and named hospital deployments. Lunit does not emphasize BAC detection, focusing instead on cancer detection sensitivity. For US buyers, CureMetrix may have a regulatory advantage with FDA clearance, while Lunit appeals to internationally networked health systems.

Therapixel's MammoScreen is CE-marked in Europe and FDA-cleared in the US, with a triage and detection workflow similar to CureMetrix. Therapixel has published standalone reader studies and integrated deployment data from European national screening programs. Its pricing model includes per-exam and subscription options, offering more transparency than CureMetrix. However, Therapixel's US market presence is smaller, and its BAC capability is not highlighted. European buyers may prefer Therapixel for regulatory familiarity; US buyers seeking BAC integration should favor CureMetrix.

Koios DS focuses on breast ultrasound AI, not mammography, making it a complementary rather than competing tool. WhiteRabbit.AI offers standalone mammography triage without integrated detection, positioning it as a lighter-weight alternative to CureMetrix's dual-mode system. For health systems seeking only workflow prioritization without CAD overlay, WhiteRabbit may be more cost-effective. For those wanting both triage and detection plus cardiovascular risk scoring, CureMetrix is the more comprehensive choice, assuming budget supports the enterprise contract model.

What clinicians say

Clinician sentiment on Reddit, Doximity, and other social platforms is nonexistent. A search of r/Radiology, r/medicine, and r/Residency for CureMetrix, cmTriage, and cmAssist yielded zero relevant discussions as of May 2026. This absence is notable given that competing tools like iCAD ProFound AI and Lunit appear sporadically in radiology forum threads, often in the context of residents asking about AI-assisted reading workflows or attending radiologists debating detection accuracy.

The lack of organic chatter suggests either limited deployment footprint or a tool architecture that radiologists interact with silently. If CureMetrix integrates so seamlessly into PACS that radiologists treat it as background infrastructure rather than a distinct product, it may not generate discussion. Alternatively, if adoption is concentrated in a small number of enterprise contracts with non-disclosure agreements, clinicians may be contractually restricted from public commentary. Either way, prospective buyers cannot rely on peer networks for informal validation.

Without clinician testimonials or user-generated reviews, the decision must rest on published studies and vendor-provided demonstrations. Buyers should request trial deployments with feedback surveys from their own radiologists before committing to multi-year contracts. The absence of social proof is not disqualifying, but it shifts the validation burden entirely onto the prospective customer.

What the literature says

The 2022 Journal of Breast Imaging study is the cornerstone validation paper. It reports multicenter, multivendor retrospective performance of the FDA-cleared triage algorithm across breast densities and lesion types. The study confirms that the algorithm generalizes beyond a single training institution, a necessary condition for commercial deployment. However, the retrospective design means it measures diagnostic accuracy in a controlled dataset, not prospective impact on radiologist workflows, recall rates, or patient outcomes.

The 2023 Cureus study focuses on invasive lobular carcinoma detection, a breast cancer subtype that traditional CAD systems often miss. The study evaluated biopsy-proven ILC cases and found that CureMetrix flagged lesions that radiologists initially dismissed or that older CAD systems overlooked. This is clinically meaningful because ILC presents as subtle architectural distortion rather than discrete masses, making it harder to detect. The study's limitation is its small sample size and single-institution design, which prevents generalization.

The 2026 JACC Cardiovascular Imaging study introduces the breast arterial calcification age-based percentile nomogram, linking BAC detected on mammography to cardiovascular event risk. This is a novel application of mammography AI beyond cancer detection. The study demonstrates that BAC severity, when age-adjusted, predicts cardiovascular events independently of traditional risk factors. However, the study does not evaluate whether routine BAC reporting changes clinical management or improves patient outcomes. The evidence supports BAC as a risk marker but not yet as a clinical decision tool with proven downstream benefit. The literature base is promising but incomplete, with no randomized controlled trials, no prospective recall-rate studies, and no mortality outcomes data.

Who it's for

Health system radiology departments with AI budgets and high mammography volumes are the natural fit. If your breast imaging center processes more than 5,000 mammograms annually, has dedicated IT support for PACS integration, and seeks both cancer detection improvement and workflow efficiency, CureMetrix delivers on both fronts. The added breast arterial calcification cardiovascular risk scoring creates a secondary clinical output that may justify the investment to hospital administrators focused on population health and preventive cardiology.

Chief medical information officers and radiology chiefs evaluating AI for the first time should consider CureMetrix if they value FDA clearance, multivendor validation, and invasive lobular carcinoma detection. However, they should also request trial deployments, negotiate transparent pricing with exit clauses, and compare directly against iCAD ProFound AI and Lunit INSIGHT MMG before committing. The thinner evidence base and absent clinician testimonials mean the decision rests on vendor demonstrations and pilot data rather than external validation.

Solo breast imaging practices, small community hospitals without dedicated IT teams, and academic centers with constrained budgets should hesitate. The enterprise-only pricing model, PACS integration requirements, and radiologist training overhead make CureMetrix a poor fit for resource-limited environments. These buyers should explore iCAD or Therapixel, both of which offer more transparent pricing and documented deployments in smaller settings. Alternatively, they should wait for CureMetrix to publish tiered pricing or partner with a regional health information exchange that can negotiate group rates.

The verdict

CureMetrix is a clinically credible mammography AI with FDA clearance, multivendor validation, and a unique cardiovascular risk detection feature. The invasive lobular carcinoma detection capability addresses a genuine gap in traditional CAD systems, and the breast arterial calcification nomogram positions routine mammography as a dual-purpose screening tool. For large health systems with radiology AI budgets and high screening volumes, this is a defensible choice, especially if cardiovascular risk stratification aligns with population health goals.

The evidence base is too thin for unreserved endorsement. Three peer-reviewed studies, no randomized controlled trials, no prospective recall-rate or mortality data, and zero clinician testimonials on social platforms create uncertainty about real-world adoption and satisfaction. Enterprise-only pricing with no public benchmarks forces buyers to negotiate blind, increasing procurement risk and limiting transparency. Prospective buyers should demand trial deployments, request contact with existing customers, and compare performance and pricing directly against iCAD and Lunit before signing multi-year contracts.

If you are a health system CMIO or radiology department chair with budget flexibility, pilot CureMetrix alongside a competitor and let your radiologists choose based on workflow fit and detection accuracy in your patient population. If you are a solo practice or small hospital seeking mammography AI, start with iCAD ProFound AI for its deeper evidence base and clearer pricing, or wait for CureMetrix to publish tiered options. If cardiovascular risk stratification from mammography is a strategic priority, CureMetrix is currently the only FDA-cleared option delivering that capability, making it worth the evaluation effort despite the evidence gaps.